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Abstract
Background: It is important to develop novel antipsychotics that can effectively treat schizophrenia with minor side-effects.
The aim of our work is to develop novel antipsychotics that act on dopamine D2 and D3, serotonin 5-HT1A and 5-HT2A
receptors with low affinity for the serotonin 5-HT2C and H1 receptors, which can effectively cure positive symptoms,
negative symptoms and cognitive impairment without the weight gain side-effect.
Methodology/Principal Findings: A series of 2-substituted-5-thiopropylpiperazine (piperidine) -1,3,4-oxadiazoles deriva-
tives have been synthesized and the target compounds were evaluated for binding affinities to D2, 5-HT1A and 5-HT2A
receptors. Preliminary results indicated that compounds 14, 16 and 22 exhibited high affinities to D2, 5-HT1A and 5-HT2A
receptors among these compounds. Further binding tests showed that compound 22 had high affinity for D3 receptor, and
low affinity for serotonin 5-HT2C and H1 receptors. In addition, compound 22 inhibited apomorphine-induced climbing
behavior and MK-801-induced hyperactivity with no extrapyramidal symptoms liability in mice. Moreover, compound 22
exhibited acceptable pharmacokinetic properties.
Conclusions/Significance: Compound 22 showed an atypical antipsychotic activity without liability for extrapyramidal
symptoms. We anticipate compound 22 to be useful for developing a novel class of drug for the treatment of schizophrenia.
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Introduction
Schizophrenia is a serious mental disorder that significantly
compromises the quality of life of those suffering from it. The early
agents for the treatment of psychosis, the ‘‘typical’’ antipsychotics
(haloperidol, Figure 1), were therapies for the positive symptoms of
schizophrenia, but they failed to manage its negative symptoms
and cognitive impairment [1]. Nevertheless, typical antipsychotics
carry heavy side effects such as extrapyramidal symptoms (EPS)
and hyperprolactinemia [2][3][4].
A breakthrough in the pharmacotherapy of schizophrenia was
achieved by the introduction of the ‘‘atypical’’ antipsychotics (e.g.,
clozapine, ziprasidone, risperidone, quetiapine and olanzapine)
which combines a potent antagonism for serotonin 5-HT2A with a
dopamine D2 receptors blockade [5]. A major advantage of
atypical antipsychotics is their effectiveness in suppressing negative
and cognitive symptoms [6][7][8][9][10]. However, it has been
proved that atypical antipsychotics cause numerous side effects,
such as substantial weight gain and QT interval prolongation
[11][12][13]. Therefore, the discovery of novel antipsychotic
agents that are effective and free of side effects with different
chemical structures remains a challenging.
In the past decade, experimental evidence suggested that a
complex binding profile is linked to the clinical efficacy of
antipsychotic drugs. Indeed, the importance of designing multi-
target G-protein-coupled receptors to deal with schizophrenia has
been pointed out by many authors [14][15][16]. The 5-HT1A
receptor plays crucial roles in regulating psychoemotional,
cognitive and motor functions in the central nervous system
[17][18]. Many relevant preclinical data suggested that 5-HT1A
receptor activation may contribute to the improved activity of
certain atypical antipsychotic drugs, such as treatment cognitive
and negative symptoms, and decrease the development of EPS in
schizophrenia [19]. Blockade of D2 receptor was the key
mechanism for controlling positive symptoms of schizophrenia
[20]. The localization of D3 receptor in the limbic regions of brain
suggests that this receptor subtype may be a target for developing
antipsychotics, and thus, some works suggested that D3 antago-
nism may improve cognition [21] and reduce the risk of causing
extrapyramidal side effect [22]. Compound S33138 (1) was shown
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which has been in Phase IIb clinical trials for schizophrenia [23].
Furthermore, two or more receptors may be involved in the weight
gain associated with the treatment of schizophrenia via atypical
antipsychotic drugs. Blockade of H1 receptor by antipsychotics is
more likely to be the primary cause of these adverse reactions
[24][25]. Although 5-HT2C receptor blockade has been reported
to counteract dopamine D2-mediated extrapyramidal side-effects
(EPS) [26] and may also confer anxiolytic/antidepressant
properties [27], 5-HT2C receptor may be involved in the risk of
obesity under chronic treatment [10][28][29]. Thus,the aim of our
work is to develop a novel antipsychotic that acts on dopamine D2
and D3, serotonin 5-HT1A and 5-HT2A receptors with low affinity
for the serotonin 5-HT2C and H1 receptors, so that it could
effectively cure positive symptoms, negative symptoms and
cognitive impairment without the weight gain side-effect.
In fact, some of the latest efforts in the development of novel
antipsychotic drugs are aimed at obtaining compounds with
binding affinities for a certain number of receptors
[10][30][31][32]. To validate this multireceptor affinity profile
approach to antipsychotics and to achieve an optimum interaction
with dopamine and serotonin receptors, in this work, we report the
synthesis and pharmacological evaluation of a new class of
antipsychotic agents with a 1,3,4-oxadiazole system linked to the
arylpiperazine (piperidine) group, which is one of the important
kind of drugs for CNS-activity [33][34][35]. This strategy led to
the synthesis of compounds 7–26 (Figure. 1) that allowed us to
understand the SAR (structure-activity relationship) and to
evaluate the pharmacological efficacy. The target compounds
were subjected to preliminary pharmacological evaluation to
determine their affinities for D2,D 3, 5-HT1A, 5-HT2A, 5-HT2C
and H1 receptors. Among the derivatives prepared, compound 22
exhibited high affinity to D2,D 3, 5-HT1A and 5-HT2A receptors,
with low affinity for 5-HT2C and H1 receptors. In addition,
Compound 22 inhibited apomorphine-induced climbing behavior
and MK-801-induced hyperactivity without causing catalepsy in
mice. In particular, compound 22 was more potent than
clozapine.
Results and Discussion
Synthesis of Compounds 7–26
The general strategy for the synthesis of compounds 7–26 was
summarized in Figure 2. Aromatic acids 2 were esterified with
absolute ethanol using conc. sulfuric acid as catalyst and the
resulting esters 3 were refluxed with hydrazine hydrate in ethanol
to give aroyl hydrazines 4. The acid hydrazides were then
subjected to cyclisation with carbon disulphide in the presence of
potassium hydroxide in absolute alcohol to afford the correspond-
ing 5-aryl-1,3,4-oxadiazol-2-thiones (5). Compounds 5 reacted
with 1,3-dibromopropane, in acetone to give 6. Compounds 6
reacted with an arylpiperazine (piperidine) in acetonitrile, in the
Figure 1. Title and reference compounds.
doi:10.1371/journal.pone.0035186.g001
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give compounds 7–26 (Table 1) with good yields.
In vitro studies of New Compounds
Initially, we investigated the effect of different amine moieties
(Table 2, compounds 7–12) present in several established CNS
agents: arylpiperazines such as N-(2,3-dichlorophenyl)-piperazine
present in aripiprazole, and a substituted piperidine (N-(6-fluoro-
benzisoxazol-3-yl)piperidine present in risperidone. According to
Table 2, compounds 7–10 (phenylpiperazines) showed weak
affinities for D2, 5-HT1A and 5-HT2A. It should be noted that
compounds 11 [(benzo[d]isothiazol-3-yl)piperazine] and 12 [(6-
fluorobenzo[d]isoxazol-3-yl)piperidine] displayed high affinities for
5-HT1A and 5-HT2A receptors, and increased D2 receptor affinity
in comparison to compounds 7–10.
In order to improve D2 receptor affinity, further studies were
conducted by introducing flouro, chloro, trifluoromethyl and
methoxy substituents on the phenyl of the Ar1 (Table 2,
compounds 13–20). When amine moiety Ar2 was (benzo[d]i-
sothiazol-3-yl)piperazie (compounds 13, 15, 17 and 19), the order
of affinities for the D2 and 5-HT2A receptors was
OCH3.Cl.CF3.F, and the high affinity for the 5-HT1A
substituents with Cl, but the affinities for 5-HT1A receptor were
obviously decreased when substituents with OCH3,C F 3 and F.
When amine moiety Ar2 was (6-fluorobenzo[d]isoxazol-3-yl)
piperidine (compounds 14, 16, 18 and 20), the affinities order
for the D2 receptor was OCH3.Cl.CF3.F, and the affinities
order for the 5-HT1A and 5-HT2A receptors was
OCH3.Cl.F.CF3. Compounds 14 and 16 exhibited high
affinities for D2 (compound 14, Ki=14.8 nM; compound 16,
Ki=18.3 nM), 5-HT1A (compound 14, Ki=6.8 nM; compound
16, Ki=10.5 nM) and 5-HT2A (compound 14, Ki=0.22 nM;
compound 16, Ki=6.6 nM). Moreover, compounds 14 and 16
had higher affinities for all the three receptors than clozapine (D2,
Ki=128.7 nM; 5-HT1A, Ki=141.6 nM; 5-HT2A, Ki=11.6 nM).
In particular, compounds 14 and 16 displayed higher affinities to
5-HT1A receptor than risperidone (Ki=180 nM). 5-HT1A recep-
tor implicated in the therapeutic efficacy of atypical antipsychotic
drugs in treating the negative symptoms of schizophrenia and
decreased the development of EPS in schizophrenia [18]. These
results also indicated that compounds bearing a 6-fluorobenzo[-
d]isoxazol-3-yl)piperidine moiety (14, 16, 18 and 20) showed
higher affinities to all three receptors than those with a
(benzo[d]isothiazol-3-yl)piperazine fragment (13, 15, 17 and 19).
Furthermore, we investigated the effect of replacement of the
Ar1 phenyl ring with naphthalene and heterocyclic (Table 2,
compounds 21–26). These results indicated that compounds 21
and 22 with naphthalene showed good affinities for D2, 5-HT1A
and 5-HT2A receptors. For example, compound 22 (D2,
Ki=23.0 nM; 5-HT1A, Ki=4.6 nM; 5-HT2A, Ki=1.1 nM)
showed higher affinities than clozapine (D2, Ki=128.7 nM; 5-
Figure 2. Synthesis of compounds 7–26.
doi:10.1371/journal.pone.0035186.g002
Table 1. Structure of compounds 7–26.
Compound Ar1 XA r 2
Mol.
formula
7 Ph N 2,3-di-CH3-Ph C23H28N4OS
8 Ph N 2-OCH3-Ph C22H26N4O2S
9 Ph N 2,3-di-Cl-Ph C21H22Cl2N4OS
10 Ph N 3-CF3-Ph C22H23F3N4OS
11 Ph N benzo[d]isothiazole C22H23N5OS2
12 Ph CH 6-fluoro-
benzo[d]isoxazole
C22H23FN4O2S
13 4-OCH3-Ph N benzo[d]isothiazole C23H25N5O2S2
14 4-OCH3-Ph CH 6-fluoro-
benzo[d]isoxazole
C24H25FN4O3S
15 4-Cl-Ph N benzo[d]isothiazole C22H22ClN5OS2
16 4-Cl-Ph CH 6-fluoro-
benzo[d]isoxazole
C23H22ClFN4O2S
17 4-CF3-Ph N benzo[d]isothiazole C23H22F3N5OS2
18 4-CF3-Ph CH 6-fluoro-
benzo[d]isoxazole
C24H22F4N4O2S
19 4-F-Ph N benzo[d]isothiazole C22H22FN5OS2
20 4-F-Ph CH 6-fluoro-
benzo[d]isoxazole
C23H22F2N4O2S
21 1-naphthalene N benzo[d]isothiazole C26H25N5OS2
22 1-naphthalene CH 6-fluoro-
benzo[d]isoxazole
C27H25FN4O2S
23 2-thiophene N benzo[d]isothiazole C20H21N5OS3
24 2-thiophene CH 6-fluoro-
benzo[d]isoxazole
C21H21FN4O2S2
25 4-pyridine N benzo[d]isothiazole C21H22N6OS2
26 4-pyridine CH 6-fluoro-
benzo[d]isoxazole
C22H22FN5O2S
doi:10.1371/journal.pone.0035186.t001
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pound 22 displayed higher affinity to 5-HT1A receptor than
risperidone (Ki=180 nM). However, the introduction of an
aromatic heterocycle at Ar1 (compounds 23–26) resulted in
dramatic decrease of affinities for all the three receptors. These
results pointed out the importance of the phenyl ring (Ar1) for the
affinities at the D2, 5-HT1A and 5-HT2A receptors.
In line with the multiple receptor-targeting approaches for the
development of new antipsychotic agents, compounds 14, 16, and
22 were selected for further binding tests to D3, 5-HT2C and H1
receptors because they had high affinities for D2, 5-HT1A and 5-
H ` ` `
A receptors. Previously, the D3 receptor was proposed for
atypical antipsychotic drugs, and various pharmacological studies
suggested that D3 antagonism might improve cognitive symptoms
[21] and reduce catalepsy [22]. Results showed that compounds
14, 16 and 22 displayed higher affinities to D3 receptor than
clozapine (Ki=239.8 nM). In particular, compound 22
(Ki=7.7 nM) displayed higher affinity than risperidone
(Ki=9.7 nM). Thus, these results suggested that compounds 14,
16 and 22 could reduce catalepsy in schizophrenia.
Treatment of schizophrenia with atypical antipsychotic drugs
has been associated with weight gain. Two receptors, histamine H1
and 5-HT2C, have been suggested to be involved in this adverse
event [24][25][10][28][29]. Several literatures have demonstrated
that there is significant correlation between affinity for H1 receptor
and weight gain [24][25]. As shown in Table 2, compound 22 had
much lower affinity (Ki.10000 nM) for H1 receptor than
risperidone (Ki=21.7 nM) and clozapine (Ki=3.8 nM). More-
over, compound 22 had lower affinity to the 5-HT2C receptor
(Ki.500 nM) in comparison to risperidone (Ki=14.5 nM) and
clozapine (Ki=16.2 nM). These results suggested that compound
22 exhibited a low potential to elicit treatment-caused weight gain.
Acute Toxicity
The above results led to the conclusion that compound 22
exhibited high affinity for dopamine D2 and D3, serotonin 5-HT1A
and 5-HT2A receptors, with low affinity for the serotonin 5-HT2C
and H1 receptors. We then assayed the acute toxicity of the new
compound by determining their LD50 value. Compound 22
showed good safety profiles even at the highest dose tested
(LD50.2000 mg/kg).
In vivo Studies
An initial behavioral screening was performed on compound 22
based on their multiple receptors affinity profile. The atypical
antipsychotics have been used for relieving positive symptoms at
doses without EPS [10]. In this study, the side-effect liability was
evaluated by the horizontal bar test, which is very sensitive for
catalepsy induced by dopamine D2 receptor blockade [10].
Antipsychotic potential of these compounds were assessed by
apomorphine-induced climbing and dizocilpine (MK-801) in-
duced hyperactivity. Apomorphine-induced climbing was potently
reduced by D2 receptor antagonists [36], while selective
antagonism of the effect of the noncompetitive N-methyl-D-
aspartate (NMDA) antagonist MK-801 had been proposed as a
Table 2. Binding affinities for D2,D 3, 5-HT1A, 5-HT2A, 5-HT2C and H1 receptors of compounds 7–26 and reference antipsychotics.
a
Compound Binding data of compounds, Ki±SEM (nM)
D2 5HT1A 5HT2A D3 5HT2C H1
7 .10000
b .10000
b 373.9633.0 – – –
8 .10000
b .10000
b .10000
b –––
9 .10000
b .10000
b .10000
b –––
10 .10000
b .10000
b .10000
b –––
11 2568.56321.3 19.062.3 61.465.8 – – –
12 2968.56381.1 18.961.6 11.361.2 – – –
13 96.769.5 .10000 17.261.6 – – –
14 14.861.8 6.860.7 0.2260.02 218.6635.2 19.4698.6 13.263.4
15 125.8613.5 14.261.3 27.262.8 – – –
16 18.361.6 10.561.2 6.660.8 15.561.9 501.5656.2 18.962.1
17 487.2646.3 .10000 50.865.3 – – –
18 94.568.9 51.064.9 24.762.8 – – –
19 .10000 .10000 .10000 – – –
20 125.3612.4 14.861.5 15.861.3 – – –
21 137.5613.6 345.8635.9 113.9612.1 – – –
22 23.062.6 4.660.8 1.160.1 7.760.6 860.7686.2 .10000
b
23 .10000 449.6649.8 54.166.9 – – –
24 91.0611.2 96.6610.3 50.366.5 – – –
25 .10000 .10000 389.8636.5 – – –
26 260.3632.1 60.668.6 59.267.6 – – –
risperidone 3.760.3 180615 0.1860.02 9.760.9 14.562.2 21.762.7
clozapine 128.761.9 141.661.6 11.661.3 239.8629.6 16.262.7 3.860.5
aKi values are taken from three experiments, expressed as means 6SEM.
bThe Ki values were not calculated because the inhibition percentages at 10 mM were too low.
doi:10.1371/journal.pone.0035186.t002
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schizophrenia [37].
The apomorphine-induced climbing model is based on the
induction of a hyperdopaminergic state by apomorphine. This
model has been classically linked to motor agitation and one of the
schizophrenia positive symptoms [36]. In the apomorphine-
induced climbing model, compound 22 produced the significant
reversal of apomorphine-induced climbing, with ED50 value of
3.68 mg/kg (Table 3). In comparison, risperidone, clozapine and
haloperidol produced reversal of apomorphine-induced climbing
with ED50 values of 0.02, 7.99 and 0.09 mg/kg, respectively.
These results suggested that compound 22 was slightly more
potent at blocking the D2 receptors in vivo than clozapine. This
was also consistent with their estimated Ki values at the D2
receptor.
The MK-801-induced hyperactivity model has been used to
indirectly evaluate the ability of compounds to oppose cortical
dopaminergic hypofunction induced by NMDA receptor blockade
[37]. In this test, compound 22 significantly inhibited MK-801-
induced hyperactivity with ED50 value of 3.58 mg/kg (Table 3). In
comparison, risperidone, clozapine and haloperidol yielded ED50
values of 0.01, 5.06 and 0.19 mg/kg, respectively. These results
indicated that compound 22 was more potent than clozapine.
Catalepsy is often used as the method for predicting the
incidence of extrapyramidal motor disorders. In this model
(Table 3), it was clear that haloperidol had the highest propensity
to induce catalepsy (ED50 0.22 mg/kg), in agreement with the
high capacity of this drug to block D2 receptor [38]. In contrast,
compound 22 exhibited a low potential to induce catalepsy with
ED50 value.300 mg/kg (Table 3), similar to those of risperidone
and clozapine (ED50 risperidone 0.3 mg/kg, clozapine 92.73 mg/
kg). Moreover, these results suggested that the therapeutic indices
of compound 22 calculated between their efficacy (apomorphine
or MK-801 models) and side effects (catalepsy) were in the range
81–83, while the therapeutic indices of risperidone and clozapine
were roughly 11–30. Thus, in contrast to risperidone and
clozapine, compound 22 had a high threshold for inducing
catalepsy which might, by analogy, translate into lower clinical
EPS liability.
Overall, compound 22 significantly inhibited apomorphine-
induced climbing behavior and MK-801-induced hyperactivity
without causing catalepsy. These results suggested a preferential
ability of compound 22 to modulate mesolimbic instead of
nigrostriatal dopaminergic neurotransmission, highlighting their
atypicality and low propensity to induce unwanted extrapyramidal
motor disturbances at therapeutically useful doses.
Pharmacokinetic Properties of Compound 22
Compound 22 was selected based on its in vitro profile for in vivo
characterization. Table 4 highlights the pharmacokinetic param-
eters of compound 22 in the rat using both intravenous and oral
administration. Intravenous administration of compound 22 to
rats (5 mg/kg, n=6) resulted in detectable plasma levels (half-life
(t1/2)=9.3 h), and oral administration of compound 22 to rats
(20 mg/kg, n=6) resulted in a t1/2 of 8.6 h. The area under the
curve (AUC) value of compound 22 was 6239.0 ng6h/mL after
intravenous administration versus 13602.7 ng6h/mL after oral
administration. The Cmax value after oral dosing was 723.6 ng/
mL, and the Tmax value was 5.0 h. The bioavailability of
compound 22 was 54.5%.
In summary, we described the synthesis and pharmacological
evaluation of a series of 2-substituted-5-thiopropylpiperazine
(piperidine)-1,3,4-oxadiazoles derivatives as potential multi-target
antipsychotics. Among the derivatives synthesized, compound 22
showed high affinity for dopamine D2 and D3, serotonin 5-HT1A
and 5-HT2A receptors, with low affinity for the serotonin 5-HT2C
and H1 receptors. In vivo animal models showed that compound 22
had high potential for treating symptoms of schizophrenia without
causing catalepsy. Moreover, compound 22 exhibited acceptable
pharmacokinetic properties.
Materials and Methods
Synthesis of Compounds 7–26
Melting points were determined in open capillary tubes and are
uncorrected.
1H NMR spectra were recorded at 400 MHz on a
Varian Inova Unity 200 spectrometer in CDCl3 solution.
Chemical shifts were given in d values (ppm), using tetramethylsi-
lane (TMS) as the internal standard; coupling constants (J) were
given in Hz. Signal multiplicities were characterized as s (singlet), d
(doublet), t (triplet), q (quartet), m (multiplet), br (broad signal).
Reagents were all of analytical grade or of chemical purity.
Analytical TLC was performed on silica gel GF254. Column
chromatographic purification was carried out using silica gel.
Table 3.I nvivo pharmacological profile of compound 22. Inhibition of different behavioral responses after oral administration of
the test and reference Compounds.
Compound
Apomorphine- induced
climbing (ED50, mg/kg, po, A)
MK-801-induced hyperactivity
(ED50, mg/kg, po, B)
CAT (catalepsy) (ED50 mg/kg,
po, C) C/A C/B
22 3.68 (2.79–4.86)
a 3.58 (2.59–8.28) .300 81.52 83.80
risperidone 0.02 (0.014–0.024) 0.01 (0.004–1.51) 0.3 15 30
clozapine 7.99 (7.34–8.69) 5.06 (3.41–9.69) 92.73 11.61 18.33
haloperidol 0.09 (0.054–0.177) 0.19 (0.15–0.26) 0.22 2.44 1.16
a95% Confidence limits given in parentheses.
doi:10.1371/journal.pone.0035186.t003
Table 4. Plasma pharmacokinetic data following
administration of compound 22 (i.v. dose of 5 mg/kg and p.o.
dose of 20 mg/kg) in rats (n=6/group).
Route Cmax (ng/mL) Tmax (h) t1/2 (h) AUC0-inf (ng6h/mL) F (%)
oral 723.6 5 8.6 13602.7 54.5
iv – – 9.3 6239.0
doi:10.1371/journal.pone.0035186.t004
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(a–h) [39]. A mixture of aromatic acids 2 (10 mmol), ethanol
(20 mL) and a catalytic amount of conc. H2SO4 were refluxed for
3 h. The reaction mixture was cooled and the formed solids were
filtered to give ester 3, which was refluxed with 85% hydrazine
hydrate (10 mL) in ethanol (20 mL) for 2 h. After completion of
the reaction by TLC, the reaction mixture was cooled and the
formed solids were filtered and washed with chilled ethanol (1 mL)
to give the corresponding aroyl hydrazines 4 (a–h).
benzohydrazide (4a). Yield: 88%; mp: 109–111uC (lit [40], mp:
111–113uC).
4-methoxybenzohydrazide (4b). Yield: 85%; mp: 133–135uC (lit
[41], mp: 135–137uC).
4-chlorobenzohydrazide (4c). Yield: 82%; mp: 115–117uC (lit
[41], mp: 117–118uC).
4-(trifluoromethyl)benzohydrazide (4d). Yield: 87%; mp:114–
116uC (lit [40], mp:115–116uC).
4-fluorobenzohydrazide (4e). Yield: 80%; mp: 159–162uC (lit
[41], mp: 160–163uC).
1-naphthohydrazide (4f). Yield: 80%; mp: 161–163uC (lit [41],
mp: 160–163uC).
thiophene-2-carbohydrazide (4g). Yield: 84%; mp: 136–138uC
(lit [42], mp: 135–137uC).
isonicotinohydrazide (4h). Yield: 84%; mp: 170–171uC (lit [43],
mp: 172uC).
General procedure for the preparation of 5-aryl-1,3,4-
oxadiazol-2-thiones 5 (a–h) [44]. A mixture of 10 mmol of
potassium hydroxide, 10 mmol of compounds 4 (a–h), and
15 mmol of carbon disulfide in 50 mL of absolute ethanol was
refluxed for 8 h. After the solvent was evaporated in vacuum, the
residue was dissolved in ice-cold water and acidified with dilute
hydrochloric acid. The precipitate was filtered off, washed with
water, and recrystallized from absolute ethanol to give compounds
5 (a–h).
5-phenyl-1,3,4-oxadiazole-2-thione (5a). Yield: 87%; mp: 215–
217uC (lit [45], mp: 218uC); MS (ESI) m/z 178 (M
+).
5-(4-methoxyphenyl)-1,3,4-oxadiazole-2-thione (5b). Yield:
71%; mp: 201–203uC (lit [45], mp: 204uC); MS (ESI) m/z 208
(M
+).
5-(4-chlorophenyl)-1,3,4-oxadiazole-2-thione (5c). Yield: 79%;
mp: 175–177uC (lit [45], mp: 175uC); MS (ESI) m/z 212 (M
+).
5-(4-(trifluoromethyl)phenyl)-1,3,4-oxadiazole-2-thione (5d).
Yield: 72%; mp: 168–170uC; MS (ESI) m/z 246 (M
+).
5-(4-fluorophenyl)-1,3,4-oxadiazole-2-thione (5e). Yield: 85%;
mp: 205–207uC (lit [46]. mp: 208–209uC); MS (ESI) m/z 196
(M
+).
5-(naphthalen-1-yl)-1,3,4-oxadiazole-2-thione (5f). Yield:71%;
mp: 198–200uC; MS (ESI) m/z 228 (M
+).
5-(thiophen-2-yl)-1,3,4-oxadiazole-2-thione (5g). Yield: 65%;
mp: 199–201uC (lit [47], mp: 201–203uC); MS (ESI) m/z 184
(M
+).
5-(pyridin-4-yl)-1,3,4-oxadiazole-2-thione (5h). Yield: 55%; mp:
270–271uC (lit [48], mp: 272–272.5uC; MS (ESI) m/z 179 (M
+).
General procedure for the preparation of 5-aryl-2-((3-
bromopropyl)thio)-1,3,4-oxadiazole 6 (a–h). 1,3-
dibromopropane (3 mmol) was added to a solution of
compounds 5 (a–h) (1 mmol) and potassium carbonate in
acetone (50 mL), and the mixture was refluxed for 3 h. The
progress of the reaction was monitored by TLC. After cooling to
room temperature, the mixture was filtered, the solvent was
evaporated and the residue was recrystallized from hexane/EtOH
to yield compounds 6 (a-h).
2-((3-bromopropyl)thio)-5-phenyl-1,3,4-oxadiazole (6a) : Yield:
79.1%; mp: 55–57uC.
1H-NMR (CDCl3) d 2.33–2.39 (m, 2H),
3.46 (t, 2H, J=13.6 Hz), 3.73 (t, 2H, J=12.4 Hz), 7.47–7.53 (m,
3H), 7.99–8.02 (m, 2H).
2-((3-bromopropyl)thio)-5-(4-methoxyphenyl)-1,3,4-oxadiazole
(6b) : Yield: 67.2%; mp: 65–67uC.
1H-NMR (CDCl3) d 2.32–
2.38 (m, 2H), 3.44 (t, 2H, J=14 Hz), 3.72 (t, 2H, J=12.4 Hz),
3.87 (s, 3H), 6.98–7.01 (m, 2H), 7.93–7.96 (m, 2H).
2-((3-bromopropyl)thio)-5-(4-chlorophenyl)-1,3,4-oxadiazole
(6c) : Yield: 71.1%; mp: 98–100uC.
1H-NMR (CDCl3) d 2.34–
2.37 (m, 2H), 3.46 (t, 2H, J=13.6 Hz), 3.72 (t, 2H,
J=12.4 Hz), 7.48 (d, 2H, J=8.4 Hz), 7.94 (d, 2H, J=8.4 Hz).
2-((3-bromopropyl)thio)-5-(4-fluorophenyl)-1,3,4-oxadiazole (6d)
: Yield: 74.7%; mp: 88–90uC.
1H-NMR (CDCl3) d 2.41–2.46 (m,
2H), 3.46 (t, 2H, J=13.6 Hz), 3.58 (t, 2H, J=12.4 Hz), 7.21–7.22
(m, 2H), 8.00–8.03 (m, 2H).
2-((3-bromopropyl)thio)-5-(4-(trifluoromethyl)phenyl)-1,3,4-oxa-
diazole (6e) : Yield: 70.1%; mp: 83–85uC.
1H-NMR (CDCl3) d
2.42–2.48 (m, 2H), 3.49 (t, 2H, J=13.6 Hz), 3.58 (t, 2H,
J=12.4 Hz), 7.77 (d, 2H, J=8.4 Hz), 8.13 (d, 2H, J=8.4 Hz).
2-((3-bromopropyl)thio)-5-(naphthalen-1-yl)-1,3,4-oxadiazole
(6f) : Yield: 72.8%; mp: 85–87uC.
1H-NMR (CDCl3) d 2.47–
2.51 (m, 2H), 3.51 (t, 2H, J=14 Hz), 3.61 (t, 2H, J=12.4 Hz),
7.55–7.68 (m, 3H), 7.93 (d, 1H, J=8 Hz), 8.03 (d, 1H,
J=8 Hz), 8.13 (d, 1H, J=7.2 Hz), 9.20 (d, 1H, J=8.4 Hz).
2-((3-bromopropyl)thio)-5-(pyridin-4-yl)-1,3,4-oxadiazole (6g) :
Yield: 68.7%; mp: 75–77uC.
1H-NMR (CDCl3) d 2.42–2.48 (m,
2H), 3.50 (t, 2H, J=13.6 Hz), 3.58 (t, 2H, J=12.4 Hz), 7.86–7.88
(m, 2H), 8.80–8.82 (m, 2H).
2-((3-bromopropyl)thio)-5-(thiophen-2-yl)-1,3,4-oxadiazole (6h) :
Yield: 72.5%; mp: 95–97uC.
1H-NMR (CDCl3) d 2.40–2.45 (m,
2H), 3.44 (t, 2H, J=13.6 Hz), 3.57 (t, 2H, J=12.4 Hz), 7.15–7.17
(m, 1H), 7.54–7.55 (m, 1H), 7.70–7.72 (m, 1H).
General procedure for the preparation of compounds 7–
26. To a suspension of compounds 6 (0.32 mmol) and K2CO3
(1.22 mmol) in acetonitrile (5.0 mL), arylpiperazine (piperidine)
(0.32 mmol) and a catalytic amount of KI were added and the
resulting mixture was refluxed for 12 h. After filtering, the
resulting filtrate was evaporated to dryness under reduced
pressure. The residue was suspended in water (10.0 ml) and
extracted with dichloromethane (3625 mL). The combined
organic layers were evaporated under reduced pressure, and the
crude product was purified by means of chromatography (5%
MeOH/CHCl3) to yield compounds 7–26.
2-((3-(4-(2,3-dimethylphenyl)piperazin-1-yl)propyl)thio)-5-phe-
nyl-1,3,4-oxadiazole (7): Yield: 69.3%; mp: 86–88uC.
1H-NMR
(CDCl3) d 2.08 (m, 2H), 2.21 (s, 3H), 2.26 (s, 3H), 2.58 (m, 6H),
2.90 (m, 4H), 3.39 (m, 2H), 6.88–6.90 (m, 2H), 7.06 (m, 1H),
7.50 (m, 3H), 7.99–8.01 (m, 2H). MS (ESI) m/z 409.2
([M+H]
+).
2-((3-(4-(2-methoxyphenyl)piperazin-1-yl)propyl)thio)-5-phenyl-
1,3,4-oxadiazole (8).
Yield: 78.6%; oil.
1H-NMR (CDCl3) d 2.08–2.15 (m, 2H), 2.60–
2.70 (m, 6H), 3.12 (br, 4H), 3.42 (t, 2H, J=14 Hz), 3.88 (s, 3H),
6.88–7.04 (m, 4H), 7.50–7.55 (m, 3H), 8.03–8.05 (m, 2H). MS
(ESI) m/z 411.2 ([M+H]
+).
2-((3-(4-(2,3-dichlorophenyl)piperazin-1-yl)propyl)thio)-5-phe-
nyl-1,3,4-oxadiazole (9): Yield: 75.3%; mp: 82–84uC.
1H-NMR
(CDCl3) d 2.06–2.13 (m, 2H), 2.58–2.66 (m, 6H), 3.07 (br, 4H),
3.39 (t, 2H, J=14.4 Hz), 6.93–6.95 (m, 1H), 7.11–7.16 (m, 2H),
7.47–7.53 (m, 3H), 7.99–8.02 (m, 2H). MS (ESI) m/z 449.1
([M+H]
+).
2-((3-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)propyl)thio)- 5-
phenyl-1,3,4-oxadiazole.
(10): Yield: 67.2%; mp: 68–69uC.
1H-NMR (CDCl3) d 2.06–
2.13 (m, 2H), 2.56–2.64 (m, 6H), 3.24 (t, 4H, J=10 Hz), 3.39 (t,
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7.53 (m, 3H), 7.99–8.02 (m, 2H). MS (ESI) m/z 449.2 ([M+H]
+).
2-((3-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)propyl)thio)-5-
phenyl-1,3,4-oxadiazole (11): Yield: 69.1%; mp: 69–71uC.
1H-
NMR (CDCl3) d 2.11–2.14 (m, 2H), 2.64 (t, 2H, J=13.6 Hz),
2.72–2.74 (m, 4H), 3.40 (t, 2H, J=14 Hz), 3.58–3.60 (m, 4H),
7.33–7.37 (m, 1H), 7.44–7.52 (m, 4H), 7.80 (d, 1H, J=8 Hz),
7.89 (d, 1H, J=8.4 Hz), 7.99 (d, 2H, J=2 Hz). MS (ESI) m/z
438.2 ([M+H]
+).
2-(3-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)propylthio)-
5-phenyl-1,3,4-oxadiazole (12): Yield: 81.6%; mp: 106–107uC.
1H-NMR (CDCl3) d 2.05–2.18 (m, 8H), 2.57 (t, 2H,
J=13.6 Hz), 3.05–3.09 (m, 3H), 3.40 (t, 2H, J=14.4Hz), 7.05
(m, 1H), 7.24 (dd, 1H, J1=2 Hz, J2=2 Hz), 7.49–7.51 (m, 3H),
7.68–7.71 (m, 1H), 7.99–8.02 (m, 2H). MS (ESI) m/z 439.2
([M+H]
+).
2-((3-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)propyl)thio)-5-(4-
methoxyphenyl)-1,3,4-.
oxadiazole (13): Yield: 70.6%; mp: 88–89uC.
1H-NMR (CDCl3)
d 2.08–2.11 (m, 2H), 2.61 (t, 2H, J=13.6 Hz), 2.69 (t, 4H,
J=9.6 Hz), 3.38 (t, 2H, J=14.4 Hz), 3.57 (t, 4H, J=9.6 Hz), 3.87
(s, 3H), 6.99 (d, 2H, J=8.8 Hz), 7.35 (t, 1H, J=8.4 Hz), 7.46 (t,
1H, J=8.8 Hz), 7.80 (d, 1H, J=8.4 Hz), 7.89–7.95 (m, 3H). MS
(ESI) m/z 468.2 ([M+H]
+).
2-(3-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)propylthio)-
5-(4-methoxyphenyl)-1,3,4-oxadiazole (14): Yield: 78.3%; mp:
103–104uC.
1H-NMR (CDCl3) d 2.04–2.17 (m, 8H), 2.57 (t,
2H, J=13.6 Hz), 3.04–3.08 (m, 3H), 3.37 (t, 2H, J=14 Hz),
3.86 (s, 3H), 6.99–7.07 (m, 3H), 7.21–7.30 (m, 1H), 7.68–7.71
(m, 1H), 7.91–7.95 (m, 2H). MS (ESI) m/z 469.2 ([M+H]
+).
2-((3-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)propyl)thio)-5-(4-
chlorophenyl)-1,3,4-.
oxadiazole (15): Yield: 79.8%; mp: 99–101uC.
1H-NMR
(CDCl3) d 2.08–2.12 (m, 2H), 2.59–2.71 (m, 6H), 3.40 (t, 2H,
J=14.4 Hz), 3.55–3.58 (m, 4H), 7.33–7.36 (m, 1H), 7.44–7.47 (m,
3H), 7.79–7.89 (m, 1H), 7.90–7.94 (m, 3H). MS (ESI) m/z 472.2
([M+H]
+).
2-(3-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)propylthio)-
5-(4-chlorophenyl)-1,3,4-.
oxadiazole (16): Yield: 80.3%; mp: 115–117uC.
1H-NMR
(CDCl3) d 2.08–2.20 (m, 8H), 2.56–2.59 (m, 2H), 3.06–3.09 (m,
3H), 3.42 (t, 2H, J=14.4 Hz), 7.04–7.06 (m, 1H), 7.22–7.24 (m,
1H), 7.46–7.49 (m, 2H), 7.68–7.72 (m, 1H), 7.94–7.96 (m, 2H).
MS (ESI) m/z 473.2 ([M+H]
+).
2-((3-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)propyl)thio)-5-(4-
(trifluoromethyl)phenyl)-.
1,3,4-oxadiazole (17): Yield: 71.8%; mp: 106–107uC.
1H-NMR
(CDCl3) d 2.10–2.14 (m, 2H), 2.60–2.71 (m, 6H), 3.43 (t, 2H,
J=14 Hz), 3.58 (br, 4H), 7.33–7.37 (m, 1H), 7.44–7.48 (m, 1H),
7.75–7.82 (m, 3H), 7.90 (d, 1H, J=8 Hz), 8.13 (d, 2H, J=8 Hz).
MS (ESI) m/z 506.2 ([M+H]
+).
2-(3-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)propylthio)-
5-(4-(trifluoromethyl)phenyl)-1,3,4-oxadiazole (18): Yield: 68.4%;
mp: 122–124uC.
1H-NMR (CDCl3) d 2.08–2.19 (m, 8H), 2.59
(t, 2H, J=13.6 Hz), 3.06–3.12 (m, 3H), 3.43 (t, 2H, J=14 Hz),
7.06–7.08 (m, 1H), 7.23–7.27 (m, 2H), 7.68–7.72 (m, 1H), 7.77
(d, 2H, J=8.4 Hz), 8.14 (d, 1H, J=8 Hz). MS (ESI) m/z 507.2
([M+H]
+).
2-(3-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)propylthio)-5-(4-
fluorophenyl)-1,3,4-.
oxadiazole (19): Yield: 71.2%; mp: 89–91uC.
1H-NMR (CDCl3)
d 2.06–2.10 (m, 2H), 2.57–2.68 (m, 6H), 3.38 (t, 2H, J=14 Hz),
3.53–3.56 (m, 4H), 7.13–7.17 (m, 2H), 7.32–7.43 (m, 2H), 7.77–
7.99 (m, 4H). MS (ESI) m/z 456.2 ([M+H]
+).
2-(3-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)propylthio)-
5-(4-fluorophenyl)-1,3,4-.
oxadiazole (20): Yield: 61.9%; mp: 118–120uC.
1H-NMR
(CDCl3) d 2.05–2.17 (m, 8H), 2.57 (t, 2H, J=13.6 Hz), 3.05–
3.07 (m, 3H), 3.40 (t, 2H, J=14 Hz), 7.05–7.06 (m, 1H), 7.16–
7.25 (m, 3H), 7.68–7.71 (m, 1H), 8.00–8.03 (m, 2H). MS (ESI) m/
z 457.2 ([M+H]
+).
2-(3-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)propylthio)-5-
(naphthalen-1-yl)-1,3,4-.
oxadiazole (21): Yield: 66.9%; oil.
1H-NMR (CDCl3) d 2.11–
2.18 (m, 2H), 2.62–2.72 (m, 6H), 3.44 (t, 2H, J=14 Hz), 3.56–
3.59 (m, 4H), 7.32–8.13 (m, 10H), 9.21 (d, 1H, J=8.8 Hz). MS
(ESI) m/z 488.3 ([M+H]
+).
2-(3-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)propylthio)-
5-(naphthalen-1-yl)-1,3,4-.
oxadiazole (22): Yield: 76.8%; mp: 107–109uC.
1H-NMR
(CDCl3) d 2.06–2.16 (m, 8H), 2.60 (t, 2H, J=6.8 Hz), 3.07–3.10
(m, 3H), 3.45 (t, 2H, J=14 Hz), 7.04–7.06 (m, 1H), 7.23–7.26 (m,
1H), 7.56–7.59 (m, 2H), 7.67–7.69 (m, 2H), 7.92 (d, 1H,
J=8.4 Hz), 8.02 (d, 1H, J=8 Hz), 8.13 (d, 1H, J=7.2 Hz), 9.21
(d, 1H, J=8.8 Hz). MS (ESI) m/z 489.3 ([M+H]
+).
2-(3-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)propylthio)-5-
(thiophen-2-yl)-1,3,4-.
oxadiazole (23): Yield: 68.5%; mp: 65–67uC.
1H-NMR (CDCl3)
d 2.07–2.11 (m, 2H), 2.60 (t, 2H, J=13.6 Hz), 2.68–2.70 (m, 4H),
3.38 (t, 2H, J=14 Hz), 3.55–3.58 (m, 4H), 7.13–7.15 (m, 1H),
7.35 (m, 1H), 7.44–7.47 (m, 1H), 7.51–7.53 (m, 1H), 7.69–7.70 (m,
1H), 7.80 (d, 1H, J=8 Hz), 7.90 (d, 1H, J=8.4 Hz). MS (ESI) m/
z 444.2 ([M+H]
+).
2-(3-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)propylthio)-
5-(thiophen-2-yl)-1,3,4-.
oxadiazole (24): Yield: 60.3%; mp: 91–92uC.
1H-NMR (CDCl3)
d 2.04–2.17 (m, 8H), 2.56 (t, 2H, J=13.6 Hz), 3.05–3.07 (m, 3H),
3.38 (t, 2H, J=14.4 Hz), 7.05–7.08 (m, 1H), 7.14–7.16 (m, 1H),
7.22–7.25 (m, 1H), 7.52–7.54 (m, 1H), 7.68–7.71 (m, 2H). MS
(ESI) m/z 445.2 ([M+H]
+).
2-(3-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)propylthio)-5-
(pyridin-4-yl)-1,3,4-oxadiazole (25): Yield: 66.3%; mp: 93–94uC.
1H-NMR (CDCl3) d 2.09–2.12 (m, 2H), 2.59–2.71 (m, 6H),
3.44 (t, 2H, J=14 Hz), 3.56 (t, 4H, J=9.6 Hz), 7.33–7.36 (m,
1H), 7.44–7.47 (m, 1H), 7.79–7.91 (m, 4H), 8.78–8.80 (m, 2H).
MS (ESI) m/z 439.2 ([M+H]
+).
2-(3-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)propylthio)-
5-(pyridin-4-yl)-1,3,4-.
oxadiazole (26): Yield: 71.2%; mp: 115–117 uC.
1H-NMR
(CDCl3) d 2.06–2.19 (m, 8H), 2.59 (t, 2H, J=13.6 Hz), 3.06–3.10
(m, 3H), 3.44 (t, 2H, J=14 Hz), 7.03–7.08 (m, 1H), 7.23–7.26 (m,
1H), 7.68–7.72 (m, 1H), 7.86–7.87 (m, 2H),8.79–8.81 (m, 2H). MS
(ESI) m/z 440.2 ([M+H]
+).
Ethics Statement
Chinese Kun Ming (KM) Mice (2062.0 g) and Sprague-
Dawley (SD) rats (25065.0 g) were used as experimental animals
in this study. Animals were housed under standardized conditions
for light and temperature and received standard rat chow and tap
water and libitum. Animals were randomly assigned to different
experimental groups and each group was kept in a separate cage.
All the research involving animals in this study follows the
guidelines of the byelaw of experiments on animals, and has been
approved by the Ethics and Experimental Animal Committee of
Jiangsu Nhwa Pharmaceutical Co., Ltd.
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General procedures. All the new compounds were dissolved
in 5% DMSO. The following specific radioligands and tissue
sources were used: (a) serotonin 5-HT1A receptor, [
3H]8-OH-
DPAT, rat brain cortex; (b) serotonin 5-HT2A receptor,
[
3H]ketanserin, rat brain cortex; (c) serotonin 5-HT2C receptor,
[
3H]mesulergine, rat brain cortex; (d) dopamine D2 receptor,
[
3H]spiperone, rat striatum; (e) dopamine D3 receptor,
[
3H]spiperone, rat olfactory tubercle (f) histamine H1 receptor,
[
3H] pyrilamine, guinea pig cerebellum.
Total binding was determined in the absence of no-specific
binding and compounds. Specific binding was determined in the
presence of compounds. Non-specific binding was determined as
the difference between total and specific binding.
Percentage of inhibition (%)=(total binding 2 specific bind-
ing)6100%/(total binding 2 nonspecific binding).
Blank experiments were carried out to determine the effect of
5% DMSO on the binding and no effects were observed.
Compounds were tested at least three times over a 6 concentration
range (10
25 Mt o1 0
210 M), IC50 values were determined by
nonlinear regression analysis using Hill equation curve fitting. Ki
values were calculated based on the Cheng and Prussoff equation:
Ki=IC50/(1+C/Kd) where C represents the concentration of the
hot ligand used and Kd its receptor dissociation constant were
calculated for each labeled ligand. Mean Ki values and SEM were
reported for at least three independent experiments.
5-HT1A binding assay [49]. Rat cerebral cortex was
homogenized in 20 volumes of ice-cold Tris-HCl buffer
(50 mM, pH 7.7) using an ULTRA TURAX homogeniser, and
was then centrifuged at 32000 g for 10 min. The resulting pellet
was then resuspended in the same buffer, incubated for 10 min at
37 uC, and centrifuged at 32000 g for 10 min. The final pellet was
resuspended in Tris-HCl buffer containing 10 mM Pargyline,
4 mM CaCl2 and 0.1% ascorbic acid.
Total binding each assay tube was added 900 mL of the tissue
suspension, 50 mL of 0.5 nM [
3H]8-OH-DPAT (187.4 Ci/mmol,
Perkin Elmer Life Sciences, Boston, MA, USA), 50 mL Tris-HCl
buffer containing 10 mM Pargyline, 4 mM CaCl2 and 0.1%
ascorbic acid.
Non-specific binding each assay tube was added 900 mL of the
tissue suspension, 50 mL of 0.5 nM [
3H]8-OH-DPAT, 50 mLo f
10 mM serotonin.
Specific binding each assay tube was added 900 mL of the tissue
suspension, 50 mL of 0.5 nM [
3H]8-OH-DPAT, 50 mL of new
compounds or reference drug.
The tubes were incubated at 37uC for 30 min. The incubation
was followed by a rapid vacuum filtration through Whatman GF/
B glass filters, and the filtrates were washed twice with 5mL cold
buffer and transferred to scintillation vials. Scintillation fluid
(3.0 mL) was added and the radioactivity bound was measured
using a Beckman LS 6500 liquid scintillation counter.
5-HT2A binding assay [49]. Rat cerebral cortex was
homogenized in 20 volumes of ice-cold Tris-HCl buffer
(50 mM, pH 7.7) using an ULTRA TURAX homogeniser, and
centrifuged at 32000 g for 20 min. The resulting pellet was
resuspended in the same quantity of the buffer centrifuged for
20 min. The final pellet was resuspended in 50 volumes of the
Tris-HCl buffer.
Total binding each assay tube was added 900 mL of the tissue
suspension, 50 mL of 0.6 nM [
3H]ketanserin (60.0 Ci/mmol,
Perkin Elmer Life Sciences, Boston, MA, USA), 50 mL Tris-HCl
buffer.
Non-specific binding each assay tube was added 900 mL of the
tissue suspension, 50 mL of 0.6 nM [
3H]ketanserin, 50 mLo f
10 mM methisergide.
Specific binding each assay tube was added 900 mL of the tissue
suspension, 50 mL of 0.6 nM [
3H]ketanserin, 150 mL of new
compounds or reference drug.
The tubes were incubated at 37uC for 15 min. The incubation
was followed by a rapid vacuum filtration through Whatman GF/
B glass filters, and the filtrates were washed twice with 5 mL cold
buffer and transferred to scintillation vials. Scintillation fluid
(3.0 mL) was added and the radioactivity bound was measured
using a Beckman LS 6500 liquid scintillation counter.
5-HT2C binding assay [49]. Rat cerebral cortex was
homogenized in 20 volumes of ice-cold Tris-HCl buffer
(50 mM, pH7.7) using ULTRA TURAX homogeniser, and
centrifuged at 32000 g for 20 min. The resulting pellet was
resuspended in the same quantity of the buffer centrifuged for
20 min. The final pellet was resuspended in 50 volumes of the
Tris-HCl buffer.
Total binding each assay tube was added 900 mL of the tissue
suspension, 50 mL of 1 nM [
3H]mesulergine (85.4 Ci/mmol;
Perkin Elmer Life Sciences, Boston, MA, USA), 50 mL Tris-HCl
buffer.
Non-specific binding each assay tube was added 900 mL of the
tissue suspension, 50 mL of 1 nM [
3H]mesulergine, 50 mLo f
10 mM mianserin.
Specific binding each assay tube was added 900 mL of the tissue
suspension, 50 mL of 1 nM [
3H]mesulergine, 50 mL of new
compounds or reference drug.
The tubes were incubated at 37uC for 15 min. The incubation
was followed by a rapid vacuum filtration through Whatman GF/
B glass filters, and the filtrates were washed twice with 5 mL cold
buffer and transferred to scintillation vials. Scintillation fluid
(3.0 mL) was added and the radioactivity bound was measured
using a Beckman LS 6500 liquid scintillation counter.
D2 dopaminergic binding assay [49]. Rat striatum was
homogenized in 20 volumes of ice-cold 50 mM Tris-HCl buffer
(pH 7.7) using an ULTRA TURAX homogeniser, and
centrifuged twice for 10 min at 48,000 g with resuspension of
the pellet in fresh buffer. The final pellet was resuspended in
50 mM ice-cold Tris-HCl containing 120 mM NaCl, 5 mM KCl,
2 mM CaCl2, 1 mM MgCl2, 0.1% ascorbic acid and 5 mM
pargyline.
Total binding each assay tube was added 900 mL of the tissue
suspension, 50 mL of 0.5 nM [
3H]spiperone (16.2 Ci/mmol;
Perkin Elmer Life Sciences, Boston, MA, USA), 50 mL Tris-HCl
buffer containing 120 mM NaCl, 5 mM KCl, 2 mM CaCl2,
1 mM MgCl2, 0.1% ascorbic acid and 5 mM pargyline.
Non-specific binding each assay tube was added 900 mL of the
tissue suspension, 50 mL of 0.5 nM [
3H]spiperone, 50 mLo f
10 mM( +)-butaclamol.
Specific binding each assay tube was added 900 mL of the tissue
suspension, 50 mL of 0.5 nM [
3H]spiperone, 50 mL of new
compounds or reference drug.
The tubes were incubated at 37uC for 15 min. The incubation
was followed by a rapid vacuum filtration through Whatman GF/
B glass filters, and the filtrates were washed twice with 5 mL cold
buffer and transferred to scintillation vials. Scintillation fluid
(3.0 mL) was added and the radioactivity bound was measured
using a Beckman LS 6500 liquid scintillation counter.
D3 Dopaminergic Binding Assay [37].
Rat olfactory tubercle was homogenized in 20 volumes of ice-
cold 50 mM Hepes Na (pH 7.5) using an ULTRA TURAX
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resuspension of the pellet in fresh buffer. The final pellet was
resuspended in 50 mM Hepes Na, pH 7.5, containing 1 mM
EDTA, 0.005% ascorbic acid, 0.1% albumin, 200 nM eliprodil.
Total binding each assay tube was added 900 mL of mem-
branes, 50 mL of 0.6 nM [
3H]spiperone (16.2 Ci/mmol; Perkin
Elmer Life Sciences, Boston, MA, USA), 50 mL of 50 mM Hepes
Na, pH 7.5, containing 1 mM EDTA, 0.005% ascorbic acid,
0.1% albumin, 200 nM eliprodil.
Non-specific binding each assay tube was added 900 mLo f
membranes, 50 mLo f[
3H]spiperone, 50 mLo f1mM dopamine.
Specific binding each assay tube was added 900 mLo f
Membranes, 50 mLo f[
3H]spiperone, 50 mL of new compounds
or reference drug.
The tubes were incubated at 25uC for 60 min. The incubation
was followed by a rapid vacuum filtration through Whatman GF/
B glass filters, and the filtrates were washed twice with 5 mL cold
buffer and transferred to scintillation vials. Scintillation fluid
(3.0 mL) was added and the radioactivity bound was measured
using a Beckman LS 6500 liquid scintillation counter.
Histamine H1 Binding Assay [50]
Guinea pig cerebellum was homogenized in 20 volumes of ice-
cold 50 mM phosphate buffer (pH 7.4) using an ULTRA
TURAX homogeniser, and centrifuged twice for 10 min at
50,000 g with resuspension of the pellet in fresh buffer. The final
pellet was resuspended in phosphate buffer.
Total binding each assay tube was added 900 mL of membranes
50 mL of 1 nM [
3H]pyrilamine (20.0 Ci/mmol; Perkin Elmer Life
Sciences, Boston, MA, USA), 50 mL phosphate buffer.
Non-specific binding each assay tube was added 900 mLo f
membranes, 50 mLo f[
3H]pyrilamine, 50 mLo f1mM prometh-
azine.
Specific binding each assay tube was added 900 mLo f
Membranes, 50 mLo f[
3H]pyrilamine, 50 mL of new compounds
or reference drug.
The tubes were incubated at 30uC for 60 min. The incubation
was followed by a rapid vacuum filtration through Whatman GF/
B glass filters, and the filtrates were washed twice with 5 mL cold
buffer and transferred to scintillation vials. Scintillation fluid
(3.0 mL) was added and the radioactivity bound was measured
using a Beckman LS 6500 liquid scintillation counter.
Acute toxicity study. Mice (5 mice in each group) were
orally dosed with increasing doses of the compound 22 (200, 500,
1000, 1500 and 2000 mg/kg). The number of surviving animals
was recorded after 24 h of drug administration, and the percent
mortality in each group was calculated. The LD50 value was
calculated by using the program SPSS (Statistical Package for the
Social Science).
MK-801-induced hyperactivity [51]. Mice (10 mice in
each group) were orally dosed with vehicle or increasing doses of
the haloperidol (0.06, 0.2, 0.6, 2.0 and 6 mg/kg), clozapine (1, 2.5,
7, 20 and 60 mg/kg), risperidone (0.01, 0.03, 0.1, 0.3 and 1.0 mg/
kg) and compound 22 (3, 5, 10, 20 and 30 mg/kg). Animals were
placed in Plexiglas cages for evaluating locomotor activity. After
30 min, the animals were challenged with 0.3 mg/kg (sc) of MK-
801 and the locomotor activity of each animal was recorded for
90 min.
Behavioral Tests
Apomorphine-induced climbing [36]. Mice (10 mice in
each group) were orally dosed with vehicle or increasing doses of
the haloperidol (0.1, 0.13, 0.17, 0.23 and 0.3 mg/kg), clozapine
(4.0, 7.5, 9.5 and 12.5 mg/kg), risperidone (0.01, 0.03, 0.1 and
0.3 mg/kg), compound 22 (0.8, 2.5, 8, 25 and 80 mg/kg). Animals
were then challenged at 30 minutes post-injection with 1.0 mg/kg
of the apomorphine in 0.9% NaCl+0.1% ascorbic acid, placed in
cylindrical wire cages (12 cm in diameter, 14 cm in height), and
observed for climbing behavior at 10, 20 and 30 min post dose.
The climbing behaviour was scored as follows: 3–4 paws on the
cage floor=0 score; 2 and 3 paws on the cage=1 score; 4 paws on
the cage=2 score.
Catalepsy test [38]. Mice (10 mice in each group) were
orally dosed with vehicle or increasing doses of the haloperidol
(0.18, 0.35, 0.75, 1.5 and 3.0 mg/kg), clozapine (25, 50, 100, 150
and 200 mg/kg), risperidone (0.1, 0.6, 1.2, 2.5 and 5.0 mg/kg),
compound 22 (50, 150 and 300 mg/kg). Catalepsy was evaluated
on a metal bar 0.6 cm in diameter positioned 4.5 cm above the
tabletop. The test consisted in positioning the animal with its
forepaws on the bar and recording how long it remained hanging
onto the bar; the end-point was 60 s and an all-or-none criterion
was used.
Pharmacokinetics study in rat. The HPLC conditions
were as follows: column, Shim-pack ODS
5.0 mm6150 mm62.0 mm I.D (SHIMADZU, Japanese); mobile
phase, 0.0167% HCOOH (TEDIA Company, USA)/acetonitrile
(Merck Company, Germany)50/50; flow rate, 0.2 mL/min;
column temperature, 40uC.
For routine compound 22 screening rats (n=6/group) were
dosed via the lateral tail vein at the indicated dose for intravenous
administration (5 mg/kg, 100% saline) or via oral gavage (20 mg/
kg, suspension in 0.5% methylcellulose). At 30 min, 1 h, 2 h, 3 h,
4 h, 5 h, 6 h, 7 h and 24 h after administration, serial blood
samples were collected from the lateral tail vein into heparinized
collection tubes (approximately 0.25 mL). The plasma was
separated by centrifugation, and the sample was prepared for
analysis HPLC/MS by protein precipitation with acetonitrile. The
plasma samples were analyzed for drug and internal standard via
HPLC-MS/MS protocol.
Statistics. To estimate the potency of test and reference
compounds, the ED50 values and their 95% confidence limits were
calculated by using the program SPSS (Statistical Package for the
Social Science).
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